Compare Incyte Corporation (INCY) vs Rush Street Interactive Inc (RSI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Rush Street Interactive Inc — how do they compare? Incyte Corporation trades at $115.7 (market cap $23.11B), while Rush Street Interactive Inc trades at $33.46 (market cap $3.55B). The key difference: Incyte Corporation is far larger — about 6.5× Rush Street Interactive Inc's market cap. Which is the better fit depends on your goals.
| INCY | RSI | |
|---|---|---|
Market Cap | $23.11B | $3.55B |
Sector | Health | Technology |
52-Week High | $118.52 | $34.52 |
52-Week Low | $67.38 | $14.55 |
Enterprise Value | $19.13B | $3.23B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Rush Street Interactive (RSI) trades at $34.52, up 6.22% over 24 hours, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q1 2026 EPS of $0.14, beating expectations, and maintains strong revenue growth projections for 2026. Recent expansion into Alberta and positive analyst coverage highlight operational momentum amid a high valuation multiple.
Outlook remains positive with 77% analyst buy ratings and a consensus price target of $30.44, though the stock trades above target. Risks include elevated P/E of 95.59 and net margin pressure at 2.98%. Earnings on July 29, 2026, will be critical for validating growth trajectory amid competitive and regulatory headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Rush Street Interactive Inc
Rush Street Interactive, Inc. is a digital gaming and sports betting company operating in the regulated U.S. and international markets. The company owns and operates online casino (iGaming) and sports wagering platforms, including BetRivers and PlaySugarHouse brands. RSI focuses on providing a secure and high-quality online gaming experience, leveraging its proprietary technology platform and commitment to responsible gaming.
Read more on RSI →
